Aster DM Healthcare Ltd. is an Indian conglomerate healthcare provider. It operates medical centres, diagnostic centres, laboratories, hospitals, and pharmacies in the Middle East and India. The company was incorporated in 1987 with headquarters in Dubai, UAE. During FY 2021-2022, Aster DM Healthcare Ltd. Reported a total revenue of Rs 10,303.94 crore, up 19.01% against Rs 8,658.40 crore recorded in the previous financial year, 2020-2021. On 14 October 2022, the company’s market capitalisation stood at Rs 12,080 crore.
The company is listed on the Bombay Stock Exchange with the code 540975, and on the National Stock Exchange with the code ASTERDM.
Aster DM Healthcare Ltd. provides services in areas like dental, diabetology, general medicine, cardiology, dermatology, endocrinology, dietetics, ENT, general surgery, neurology, orthopaedics, psychiatry, gynaecology, gastroenterology, ophthalmology, paediatrics, pulmonology, and urology. The company was formerly called Dr Moopen Group and changed its name to DM Healthcare Ltd. in 2008.
On 30 June 2022, the company’s shareholding pattern showed a 37.88% promoter stake, 11.44% foreign institutional investor stake, 9.65% domestic institutional investor stake, and 40.57% public stake. Union Investments Pvt Ltd. is the leading promoter with a 37.41% stake. In the June 2022 quarter, the promoters’ pledge remained unchanged at 10.44% of the holdings, while mutual fund holdings increased from 8.12% to 9.62%.
The founder of Aster DM Healthcare Ltd. is Mr Azad Moopen. The company’s leadership team comprises Ms Fara Siddiqui, Dr Malathi Arshanapalai, Mr Veneeth Purushotaman, Dr Shanila Laiju, Mr Brandon Rowberry, Mr N S Balasubramanian, Mr T J Wilson, Ms Alisha Moopen, and Mr Sreenath P Reddy. Its auditors are Deloitte Haskins & Sells. As of 30 June 2022, the company had a total of 49.95 crore shares outstanding.
On 14 October 2022, the company’s share price closed at Rs 241.90 on BSE. It closed at Rs 241.85 on NSE. Aster DM Healthcare Ltd.’s 52-week high share price was Rs 265.55, and the 52-week low share price was Rs 158.
The company’s peers include Apollo Hospitals Enterprises Ltd., Max Healthcare Institute Ltd., Fortis Healthcare Ltd., and Dr Lal PathLabs Ltd.
As of September 2022, HDFC Small Cap Fund had a 3.01% stake in the company. SBI Contra Fund, ICICI Prudential Smallcap Fund, and HDFC Children’s Gift Fund had 2.19%, 1.83%, and 1.49% stakes, respectively.
Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code :07730), BSE Ltd (Member Code :103) and Member of Multi Commodity Exchange of India Ltd. (Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Mr. Anoop Goyal, Contact number: 022-40701000, E-mail address: complianceofficer@icicisecurities.com. Investment in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose